StockNews.com began coverage on shares of Chemours (NYSE:CC – Get Rating) in a report released on Thursday. The firm set a “hold” rating on the specialty chemicals company’s stock.
A number of other analysts also recently weighed in on CC. Credit Suisse Group increased their price target on shares of Chemours from $24.00 to $27.00 and gave the company an “underperform” rating in a report on Friday, February 10th. The Goldman Sachs Group increased their price target on shares of Chemours from $34.00 to $38.00 and gave the company a “neutral” rating in a report on Tuesday, February 14th. Citigroup increased their price target on shares of Chemours from $33.00 to $35.00 and gave the company a “neutral” rating in a report on Monday, February 13th. UBS Group raised shares of Chemours from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $31.00 to $43.00 in a report on Tuesday, January 24th. Finally, Bank of America raised shares of Chemours from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $37.00 to $40.00 in a report on Wednesday, January 11th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $36.33.
Chemours Stock Performance
NYSE:CC opened at $28.57 on Thursday. Chemours has a 1 year low of $23.58 and a 1 year high of $44.95. The firm’s fifty day simple moving average is $34.01 and its 200 day simple moving average is $31.64. The company has a current ratio of 1.70, a quick ratio of 0.96 and a debt-to-equity ratio of 3.24. The firm has a market capitalization of $4.24 billion, a PE ratio of 8.00, a PEG ratio of 1.25 and a beta of 1.88.
Insider Activity at Chemours
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently bought and sold shares of the company. Raymond James & Associates lifted its position in Chemours by 31.0% during the 1st quarter. Raymond James & Associates now owns 135,617 shares of the specialty chemicals company’s stock worth $4,269,000 after buying an additional 32,121 shares in the last quarter. Cetera Advisor Networks LLC increased its stake in shares of Chemours by 21.3% during the 1st quarter. Cetera Advisor Networks LLC now owns 9,636 shares of the specialty chemicals company’s stock worth $303,000 after purchasing an additional 1,695 shares during the last quarter. Bank of Montreal Can increased its stake in shares of Chemours by 36.4% during the 1st quarter. Bank of Montreal Can now owns 73,197 shares of the specialty chemicals company’s stock worth $2,361,000 after purchasing an additional 19,552 shares during the last quarter. D.A. Davidson & CO. acquired a new position in shares of Chemours during the 1st quarter worth about $208,000. Finally, MetLife Investment Management LLC increased its stake in shares of Chemours by 35.7% during the 1st quarter. MetLife Investment Management LLC now owns 107,133 shares of the specialty chemicals company’s stock worth $3,373,000 after purchasing an additional 28,160 shares during the last quarter. Institutional investors own 71.89% of the company’s stock.
About Chemours
The Chemours Co is a holding company, which engages in the provision of performance chemicals. The firm delivers solutions, which include a range of industrial and chemical products for markets including coatings, plastics, refrigeration and air conditioning, transportation, semiconductor and consumer electronics, and general industrial.
Featured Stories
- Get a free copy of the StockNews.com research report on Chemours (CC)
- Meta Platforms: Efficiency Gains Momentum, Stock Accelerates
- Pfizer’s Latest Acquisition Strengthens the Case for PFE Stock
- SentinelOne: Reversal In-Play For Cybersecurity Stocks
- Is Sportradar Group A Growth Stock To Bet On In 2023?
- Strong Guidance says Boeing is Ready for Takeoff
Receive News & Ratings for Chemours Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours and related companies with MarketBeat.com's FREE daily email newsletter.